Incidence of ventilator associated pneumonia and drug-resistant bacterial preponderance: a fact to ponder


  • Johny G. Asir Department of Microbiology, Pondicherry Institute of Medical Sciences, Pondicherry, India
  • Vidya Jayasekaran Department of Microbiology, Pondicherry Institute of Medical Sciences, Pondicherry, India
  • Vadivu Shanmugam Department of Nursing, Mahatma Gandhi Medical College, Pondicherry, India
  • Sujitha Elan Department of Microbiology, Pondicherry Institute of Medical Sciences, Pondicherry, India
  • Reba Kanungo Department of Microbiology, Pondicherry Institute of Medical Sciences, Pondicherry, India



Acinetobacter, Bacteria, Drug resistance, VAP


Background: Management of ventilator-associated pneumonia (VAP) in critically ill patients is a challenge to intensivists. This study aimed at identifying microbial factors and infection control practices that influenced incidence of VAP in a tertiary care hospital.

Methods: Incidence of VAP among patients admitted to the intensive care units (ICU) from January to December 2016 was estimated. A one year period of study was divided into 3 segments of January to April, May to August, and September to December. Isolation rates of Gram Negative Bacteria (GNB) from respiratory samples and their extensively drug resistance (XDR) pattern were also analyzed.

Results: A total of 14 patients had developed VAP. Incidence of VAP in the 1st, 2nd and 3rd segments of the year was 25.3, 15.2 and 4.1/1000 ventilator days respectively. Acinetobacter baumannii was the causative agent in all patients (100%). Among all GNB isolated the rate of Acinetobacter baumannii was 83%, 64%, 59% during the 3 segments of the year. XDR strains were 76%, 62% and 55%. Interventional factors like improvement in infection control practices which included hand hygiene, cohorting of MDR/XDR infected patients and environmental surveillance was noted.

Conclusions: The VAP incidence declined in the later part of the year than the earlier (25.3 Vs 4.1/1000 ventilator days), with a notable decrease in the isolation of Acinetobacter baumannii (p value-0.005) and XDR organisms (p value-0.01). Directly proportionate association of VAP incidence with microbial factors were noted. Infection control measures to curtail MDR organisms should be an important component in the management of patients on ventilators.


Nair GB, Neiderman MS. Ventilator associated Pneumonia: Present understanding and ongoing debates. Intensive care Med. 2015:41;34-48.

American Thoracic Society, Infectious Diseases Society of America: Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia. Am J Respir Crit Care Med. 2005; 171:388-416.

Inchai J, Pothirat C, Liwsrisakun C, Deesomchok A, Kositsakulchai W, Chalermpanchai N. Ventilator-associated pneumonia: epidemiology and prognostic indicators of 30-day mortality. Japanese J Infect Dis. 2015;68(3):181-6.

Erfani Y, Rasti A, Janani L. Prevalence of Gram-negative bacteria in ventilator-associated pneumonia in neonatal intensive care units: a systematic review and meta-analysis protocol. BMJ Open. 2016;6(10):e012298.

Nseir S, Blazejewski C, Lubret R, Wallet F, Courcol R, Durocher A. Risk of acquiring multidrug-resistant Gram negative bacilli from prior room occupants in the intensive care unit. Clin Microbiol Infect. 2011;17:1201-8.

Li YC, Lin HL, Liao FC, Wang SS, Chang HC, Hsu HF, Chen SH, Wan GH. Potential risk for bacterial contamination in conventional reused ventilator systems and disposable closed ventilator-suction systems. PloS one. 2018 Mar 16;13(3):e0194246.

Seham FA, Hanan SS, Safaa HS, Wafaa FE, Mona ME, Ahmed G. Reducing ventilator-associated pneumonia in neonatal intensive care unit using VAP prevention Bundle: a cohort study. BMC Infect Dis. 2015; 15:314-21.

Klompas M. Clinician's Corner: Does this patient have ventilator-associated pneumonia? JAMA. 2013;297:1583-93.

Magiorakos AP, Srinivasan A, Carey RB, Carmeli Y, Falagas ME, Giske CG et al. Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance Clin Microbiol Infect. 2012;18:268-28.

Mathai AS, Phillips A, Isaac R. Ventilator-associated pneumonia: A persistent healthcare problem in Indian Intensive Care Units!. Lung India: official organ of Indian Chest Society. 2016 Sep;33(5):512.

Chawla R. Epidemiology, etiology, and diagnosis of hospital-acquired pneumonia and ventilator-associated pneumonia in Asian countries. Am J Infection Control. 2008 May 1;36(4):S93-100.

Joseph NM, Sistla S, Dutta TK, Badhe AS, Parija SC. Ventilator associated pneumonia in a tertiary care hospital in India: Incidence and risk factors. J Infect Dev Ctries. 2009;3:771 7.

Rosenthal VD, Al-Abdely HM, El-Kholy AA, AlKhawaja SA, Leblebicioglu H, Mehta Y et al. International Nosocomial Infection Control Consortium report, data summary of 50 countries for 2010-2015: Device-associated module. Am J Infect Control. 2016;44:1495-1504.

Timsit JF, Esaied W, Neuville M, Bouadma L, Mourvllier B. Update on ventilator-associated pneumonia. F1000Research. 2017;6.

1WHO. Global priority list of antibiotic-resistant bacteria to guide research, discovery, and development of new antibiotics. Available at Accessed 30 May 2018.

Jordi Rello, Emili D, Alejandro Rodrıguez. Etiology of Ventilator-Associated Pneumonia. Clin Chest Med. 2005;26:87-95.

Alp E, Voss A. Ventilator associated pneumonia and infection control. Ann Clin Microbiol Antimicrobials. 2006 Jan;5(1):7.

Ranjan N, Chaudhary U, Chaudhry D, Ranjan KP. Ventilator-associated pneumonia in a tertiary care intensive care unit: Analysis of incidence, risk factors and mortality. Indian journal of critical care medicine: peer-reviewed, official publication of Indian Soc Critical Care Med. 2014 Apr;18(4):200-4.

Martin-Loeches I, Povoa P, Rodríguez A, Curcio D, Suarez D, Mira JP, et al. Incidence and prognosis of ventilator-associated tracheobronchitis (TAVeM): a multicentre, prospective, observational study. Lancet Resp Med. 2015 Nov 1;3(11):859-68.

Tsakiridou E, Makris D, Daniil Z, Manoulakas E, Chatzipantazi V, Vlachos O, et al. Acinetobacter baumannii infection in prior ICU bed occupants is an independent risk factor for subsequent cases of ventilator-associated pneumonia. BioMed Res Int. 2014;2014.

Mantzarlis K, Makris D, Manoulakas E, Karvouniaris M, Zakynthinos E. Risk Factors for the First Episode of Klebsiella pneumoniae Resistant to Carbapenems Infection in Critically Ill Patients: A Prospective Study. BioMed Res Inte. 2013; 2013:850547.

Kanafani ZA, Zahreddine N, Tayyar R, Sfeir J, Araj GF, Matar GM, Kanj SS. Multi-drug resistant Acinetobacter species: a seven-year experience from a tertiary care center in Lebanon. Antimicrob Resistance Inf Control. 2018 Dec;7(1):9.

Khurana S, Mathur P, Kumar S, Soni KD, Aggrawal R, Batra P, Bhardwaj N. Incidence of ventilator-associated pneumonia and impact of multidrug-resistant infections on patient's outcome: Experience at an Apex Trauma Centre in North India. Indian J Med Microbiol. 2017 Oct 1;35(4):504.

Cocanour CS, Peninger M, Domonoske BD, Li T, Wright B, Valdivia A, Luther KM. Decreasing ventilator-associated pneumonia in a trauma ICU. J Trauma Acute Care Sur. 2006 Jul 1;61(1):122-30.

Álvarez-Lerma F, Palomar-Martínez M, Sánchez-García M, Martínez-Alonso M, Álvarez-Rodríguez J, Lorente L, et al. Prevention of ventilator-associated pneumonia: the multimodal approach of the Spanish ICU Pneumonia Zero program. Critical Care Med. 2018 Feb;46(2):181.




How to Cite

Asir, J. G., Jayasekaran, V., Shanmugam, V., Elan, S., & Kanungo, R. (2018). Incidence of ventilator associated pneumonia and drug-resistant bacterial preponderance: a fact to ponder. International Journal of Research in Medical Sciences, 6(9), 3160–3165.



Original Research Articles